US FDA grants full approval of Vitrakvi (larotrectinib) for adult and paediatric patients with NTRK gene fusion-positive solid tumours

10 April 2025 - The full approval of Vitrakvi is based on the results of confirmatory trials that support Vitrakvi as ...

Read more →

argenx announces FDA approval of Vyvgart Hytrulo pre-filled syringe for self-injection in generalised myasthenia gravis and chronic inflammatory demyelinating polyneuropathy

10 April 2025 - Self-injection provides generalised myasthenia gravis and chronic inflammatory demyelinating polyneuropathy patients with flexibility for when and where to receive ...

Read more →

Biocon Biologics announces US FDA approval for Jobevne, biosimilar bevacizumab

10 April 2025 - Biocon Biologics today announced that the US FDA has approved Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab for ...

Read more →

Arcturus Therapeutics receives US FDA fast track designation for the STARR mRNA vaccine candidate ARCT-2304 for pandemic influenza A virus H5N1

10 April 2025 - Arcturus Therapeutics today announced that the US FDA has granted fast track designation for the self-amplifying mRNA ...

Read more →

Outlook Therapeutics announces acceptance of biologics license application by US FDA for ONS-5010 as a treatment for wet AMD

8 April 2025 - PDUFA goal date of 27 August 2025. ...

Read more →

Xspray Pharma re-submits its FDA application

8 April 2024 - Xspray Pharma has re-submitted its application for market approval for Dasynoc, the company's lead product candidate, an ...

Read more →

Tenpoint Therapeutics submits new drug application to US FDA for Brimichol PF for the treatment of presbyopia

8 April 2025 - NDA submission includes efficacy and safety data for the first fixed-dose combination therapy from the world’s ...

Read more →

FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

8 April 2025 - Today, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb ...

Read more →

Kura Oncology and Kyowa Kirin announce submission of new drug application for ziftomenib to FDA

8 April 2025 - Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a ...

Read more →

Teva announces FDA filing acceptance for Ajovy (fremanezumab) in paediatric episodic migraine prevention

7 April 2025 - If approved for an expanded paediatric indication, Ajovy would be the first calcitonin gene-related peptide antagonist for ...

Read more →

Allogene granted three US FDA fast track designations for ALLO-329, a next generation dual targeted CD19/CD70 allogeneic CAR T for the treatment of lupus, myositis and scleroderma

7 April 2025 - Phase 1 RESOLUTION trial initiation planned for mid-2025 with initial proof of concept by year end ...

Read more →

Update on US FDA BLA for Novavax’s COVID-19 vaccine

2 April 2025 - Novavax can confirm that 1 April 2025, was the US FDA’s Prescription Drug User Fee Act date ...

Read more →

Aldeyra Therapeutics receives complete response letter from the US FDA for the reproxalap new drug application for the treatment of signs and symptoms of dry eye disease

3 April 2025 - Pending positive results and discussions with the FDA, new drug application resubmission expected mid 2025. ...

Read more →

Uplinza (inebulizumab-cdon) is now the first and only FDA approved treatment for IgG4 related disease

3 April 2025 - Uplinza shown to deliver corticosteroid-free, flare-free, complete remission for patients in the MITIGATE trial. ...

Read more →

Platform clinical trials for the efficient evaluation of multiple treatments

31 March 2025 - For some medical conditions, including conditions without effective treatments, multiple promising but unproven therapies may exist, with ...

Read more →